o2h Ventures backs visionary teams in UK biotech, leveraging AI and data-driven approaches to accelerate drug discovery and development. The fund focuses on high-potential exits in oncology, neuroscience, and other critical disease areas, while providing SEIS/EIS tax benefits to UK investors. The team operates from Mill SciTech Park, offering incubation and grassroots scientific collaboration.
Preferred startup development maturity for initial funding deployment.
Early-stage biotech and life sciences companies, with a focus on AI-driven drug discovery, therapeutics, and digital health solutions
Core thematic spaces, technologies, and target market segments of interest.
Standard financial allocation per investment round.
Direct Verification Contact Email Pattern
Thesis Dossier Analysis Scorecard
Our agent analyzer scanned portfolio holdings and verified absolute match parameters...
